The Asia Pacific Veterinary Pain Management Market should witness market growth of 6.9% CAGR during the forecast period (2023-2030).
Veterinary pain management is identifying, preventing, and treating pain in animals that results from various reasons, including problems with their vital organs, physical wounds, surgical procedures, central nervous systems, and abnormalities with their spines. If they are to practice pain control, veterinarians must be able to recognize and treat pain in a variety of pet illnesses.
Animals can experience discomfort due to a variety of illnesses, such as arthritis, cancer, surgery, and more. Aggressive behavior, reduced or lack of activity, and other behaviors can all be pain symptoms in animals. Animals used for agriculture and companion animals may perform worse when in pain. Laser therapy, prescription medications, therapeutic massages, alternative therapies, and rehabilitation programs are some of the potential treatments.
During the forecast period, market participants will benefit from increased public-private funding for concentrated research projects, an increase in the number of pets, an increase in the number of traffic accidents involving animals, and an increase in product innovations and development due to technological advancements. Rising per capita healthcare spending, higher acceptance of unconventional and non-pharmaceutical treatment modalities, and increasing preventative care and treatment facilities for companion animals are all factors that will contribute to the market's growth in the future.
Pet ownership has become a way of life for many Chinese citizens, both young and old. In 2022, there were more than 70.43 million urban pet owners in China, a growth of 2.9 percent per year, according to a white paper on the country's pet industry released by the Chinese pet industry website pethadoop.com. Animals with a variety of diseases and injuries are being effectively treated due to the rapid development of retail and hospital pharmacies that provide veterinary drugs, dietary supplements, and pet immunizations. The market is predicted to expand significantly in the Asia Pacific region due to all these factors.
The China market dominated the Asia Pacific Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $196 million by 2030. The Japan market is estimated to witness a CAGR of 6.2% during (2023-2030). Additionally, India's market would showcase a CAGR of 7.5% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Veterinary pain management is identifying, preventing, and treating pain in animals that results from various reasons, including problems with their vital organs, physical wounds, surgical procedures, central nervous systems, and abnormalities with their spines. If they are to practice pain control, veterinarians must be able to recognize and treat pain in a variety of pet illnesses.
Animals can experience discomfort due to a variety of illnesses, such as arthritis, cancer, surgery, and more. Aggressive behavior, reduced or lack of activity, and other behaviors can all be pain symptoms in animals. Animals used for agriculture and companion animals may perform worse when in pain. Laser therapy, prescription medications, therapeutic massages, alternative therapies, and rehabilitation programs are some of the potential treatments.
During the forecast period, market participants will benefit from increased public-private funding for concentrated research projects, an increase in the number of pets, an increase in the number of traffic accidents involving animals, and an increase in product innovations and development due to technological advancements. Rising per capita healthcare spending, higher acceptance of unconventional and non-pharmaceutical treatment modalities, and increasing preventative care and treatment facilities for companion animals are all factors that will contribute to the market's growth in the future.
Pet ownership has become a way of life for many Chinese citizens, both young and old. In 2022, there were more than 70.43 million urban pet owners in China, a growth of 2.9 percent per year, according to a white paper on the country's pet industry released by the Chinese pet industry website pethadoop.com. Animals with a variety of diseases and injuries are being effectively treated due to the rapid development of retail and hospital pharmacies that provide veterinary drugs, dietary supplements, and pet immunizations. The market is predicted to expand significantly in the Asia Pacific region due to all these factors.
The China market dominated the Asia Pacific Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $196 million by 2030. The Japan market is estimated to witness a CAGR of 6.2% during (2023-2030). Additionally, India's market would showcase a CAGR of 7.5% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Scope of the Study
By Animal type
- Livestock Animal
- Companion Animal
By End-Use
- Hospitals & Clinics
- Others
By Indication
- Osteoarthritis
- Post-operative pain
- Others
By Product
- NSAIDs
- Opioids
- Anesthetics
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Veterinary Pain Management Market by Animal type
Chapter 6. Asia Pacific Veterinary Pain Management Market by End-use
Chapter 7. Asia Pacific Veterinary Pain Management Market by Indication
Chapter 8. Asia Pacific Veterinary Pain Management Market by Product
Chapter 9. Asia Pacific Veterinary Pain Management Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Methodology
LOADING...
